Jaundice differential diagnosis: Difference between revisions
No edit summary |
Ahmed Younes (talk | contribs) No edit summary |
||
(4 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
[[Image:Home_logo1.png|right|250px|link=https://www.wikidoc.org/index.php/Jaundice]] | |||
{{CMG}}; {{AE}} {{MJ}} | {{CMG}}; {{AE}} {{MJ}} | ||
== Overview == | == Overview == | ||
Jaundice is yellowish discoloration of the skin, [[conjunctiva]], and [[Mucous membrane|mucous membranes]] caused by [[hyperbilirubinemia]]. Usually, the concentration of [[bilirubin]] in the blood must exceed 2–3 mg/dL for the coloration to be easily visible | Jaundice is yellowish discoloration of the skin, [[conjunctiva]], and [[Mucous membrane|mucous membranes]] caused by [[hyperbilirubinemia]]. Usually, the concentration of [[bilirubin]] in the blood must exceed 2–3 mg/dL for the coloration to be easily visible. | ||
== Differential diagnosis of jaundice == | == Differential diagnosis of jaundice == | ||
''''' | '''''For the differential diagnosis for jaundice and RUQ pain, click [[Jaundice and RUQ pain|here]]'''.'' | ||
''''' | '''''For the differential diagnosis for jaundice and pruritis, click [[Jaundice and pruritis|here]]'''.'' | ||
''''' | '''''For the differential diagnosis for jaundice and fever, click [[Jaundice and fever|here]]'''.'' | ||
''''' | '''''For the differential diagnosis for jaundice, fever, and RUQ pain, click [[Jaundice, fever, and RUQ pain|here]]'''.'' | ||
''''' | '''''For the differential diagnosis for jaundice, pruritis and RUQ pain, click [[Jaundice, pruritis and RUQ pain|here]]'''.'' | ||
Line 161: | Line 160: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |liver biopsy | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |liver biopsy | ||
|- | |- | ||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Ischemic hepatopathy | | colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Ischemic hepatitis|Ischemic hepatopathy]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -/+ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | -/+ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
Line 176: | Line 175: | ||
|- | |- | ||
! rowspan="11" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Cholestatic Jaundice | ! rowspan="11" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Cholestatic Jaundice | ||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Common bile duct stone | | colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Common bile duct]] stone | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -/+ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | -/+ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
Line 190: | Line 189: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |CT/[[Endoscopic retrograde cholangiopancreatography|ERCP]] | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |CT/[[Endoscopic retrograde cholangiopancreatography|ERCP]] | ||
|- | |- | ||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" | | | colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Cholangitis]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +/- | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |N | ||
Line 234: | Line 233: | ||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Primary biliary cirrhosis]] | | colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Primary biliary cirrhosis]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -/+ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | -/+ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -/+ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | -/+ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
Line 274: | Line 273: | ||
| colspan="2" style="padding: 5px 5px; background: #F5F5F5;" align="center" |Genetic testing | | colspan="2" style="padding: 5px 5px; background: #F5F5F5;" align="center" |Genetic testing | ||
|- | |- | ||
| colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Pancreatic cancer|Pancreatic carcinoma]] | | colspan="1" rowspan="1" style="padding: 5px 5px; background: #DCDCDC;" align="center" |periampullary cancer | ||
([[Pancreatic cancer|Pancreatic carcinoma]], [[cholangiocarcinoma]]) | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | + | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - |
Latest revision as of 22:00, 8 February 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]
Overview
Jaundice is yellowish discoloration of the skin, conjunctiva, and mucous membranes caused by hyperbilirubinemia. Usually, the concentration of bilirubin in the blood must exceed 2–3 mg/dL for the coloration to be easily visible.
Differential diagnosis of jaundice
For the differential diagnosis for jaundice and RUQ pain, click here.
For the differential diagnosis for jaundice and pruritis, click here.
For the differential diagnosis for jaundice and fever, click here.
For the differential diagnosis for jaundice, fever, and RUQ pain, click here.
For the differential diagnosis for jaundice, pruritis and RUQ pain, click here.
Differential diagnosis of jaundice are: [1][2][3][4][5]
|
References
- ↑ Fargo MV, Grogan SP, Saguil A (2017). "Evaluation of Jaundice in Adults". Am Fam Physician. 95 (3): 164–168. PMID 28145671.
- ↑ Leevy CB, Koneru B, Klein KM (1997). "Recurrent familial prolonged intrahepatic cholestasis of pregnancy associated with chronic liver disease". Gastroenterology. 113 (3): 966–72. PMID 9287990.
- ↑ Hov JR, Boberg KM, Karlsen TH (2008). "Autoantibodies in primary sclerosing cholangitis". World J. Gastroenterol. 14 (24): 3781–91. PMC 2721433. PMID 18609700.
- ↑ Bond LR, Hatty SR, Horn ME, Dick M, Meire HB, Bellingham AJ (1987). "Gall stones in sickle cell disease in the United Kingdom". Br Med J (Clin Res Ed). 295 (6592): 234–6. PMC 1247079. PMID 3115390.
- ↑ Malakouti M, Kataria A, Ali SK, Schenker S (2017). "Elevated Liver Enzymes in Asymptomatic Patients - What Should I Do?". J Clin Transl Hepatol. 5 (4): 394–403. doi:10.14218/JCTH.2017.00027. PMC 5719197. PMID 29226106.